Ascendis Pharma Stock (NASDAQ:ASND)
Previous Close
$129.37
52W Range
$111.09 - $161.00
50D Avg
$132.41
200D Avg
$133.38
Market Cap
$7.62B
Avg Vol (3M)
$449.38K
Beta
0.65
Div Yield
-
ASND Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc. |
| BGNE | BeiGene, Ltd. |
| APLS | Apellis Pharmaceuticals, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| ACLX | Arcellx, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| BPMC | Blueprint Medicines Corporation |
| NUVL | Nuvalent, Inc. |
| REPL | Replimune Group, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| ETNB | 89bio, Inc. |
| UTHR | United Therapeutics Corporation |
| MDGL | Madrigal Pharmaceuticals, Inc. |